Laboratory assessment of SD Bioline HIV/Syphilis Duo Kit among pregnant women attending antenatal clinic Mayuge Health Center III, East central Uganda

Ivan Mugisha Taremwa1*, Alupakusadi Twelwanike1, Bashir Mwambi1 and Christine Atuhairwe2

Abstract

Objective: Efforts to dual eradication of mother-to-child transmission of human immune deficiency virus (HIV) and syphilis have improved in the previous decades. This has however been hindered by limited validation studies. A cross-sectional study was conducted among adult pregnant women attending antenatal care clinic at Mayuge Health Center III. Two milliliters of venous blood were collected into Ethylene di-amine tetra acetic acid vacutainers, and tested for HIV and syphilis using the SD Bioline HIV/Syphilis Duo assay, and the national HIV and syphilis testing algorithm. Sensitivity and specificity were calculated for the Duo Kit against the gold standards within 95% confidence intervals.

Results: Three hundred and eighty-two (382) participants were enrolled. Their mean age was 25.8 years. The prevalence of HIV was 1.8% (95% confidence interval 1.23–2.41); while that of syphilis was 2.1% (95% confidence interval 1.81–2.54), and the dual infection was 0.52% (95% confidence interval 0.37–0.92). The sensitivity and specificity of the SD Bioline HIV/Syphilis Duo assay were all 100.0% (95% confidence interval 99.5 to 100.0 and 98.6 to 100.0, respectively). The performance of the SD Bioline HIV/Syphilis Duo Kit was optimal, reassuring its aptness for use, and favorable qualities to a limited resource setting.

Keywords: HIV, Screening, Syphilis, SD Bioline Duo assay, Uganda

Introduction

The burden of HIV and syphilis infections remains high, with an estimated rates of 1.5 and 1.36 million pregnant women respectively [1–3]. Africa accounts for 42.4% of the total HIV/Syphilis burden [4], with pregnant women and newborns being amongst the at risk populations [5]. The prevalence of syphilis among pregnant women attending antenatal care in Uganda has been reported at 6.4% [6], while that of HIV at 6% [7]. The maternal effects of untreated syphilis are devastating, with pregnancy adverse outcomes like spontaneous abortion, stillbirth, fetal death, preterm birth, low birth weight and high risk of mother-to-child transmission (MTCT) [8, 9].

While antenatal syphilis and HIV screening is a policy in most countries [9], syphilis testing remains undersourced, and infected pregnant women often go undiagnosed and untreated [9]. Although multifactorial, routine syphilis screening is limited by funding and logistical drawbacks [5], and methodical single testing approaches that are often expensive [4]. To bridge the low syphilis test coverage and maximize the benefits of early HIV and syphilis testing, the World Health Organization (WHO) has commended HIV and syphilis dual screening in a combined test as part of ANC program [3, 7, 10–12]. In light of this, a point-of-care test, the SD Bioline HIV/Syphilis Duo test (Standard Diagnostics, Korea) has been invented [13]. Studies to evaluate the diagnostic performance of SD Bioline HIV/Syphilis Duo Kit among...
pregnant women have demonstrated a good clinical performance in diagnosing both HIV and syphilis [14–19]. This coupled with other attributes like being user friendly, a shorter turnaround time of 25 min and relative costs approximated to 2 USD per test [14] renders it apt. Although the SD Bioline HIV/Syphilis Duo Kit is WHO prequalified [19], its diagnostic performance has not been widely evaluated. This study determined the diagnostic performance of SD Bioline HIV/Syphilis Duo Kit among pregnant women attending antenatal care clinic at Mayuge Health Center III, Mayuge district, East central Uganda.

**Main text**

**Materials and methods**

It was a cross-sectional study conducted at Mayuge Health Center III, antenatal care unit during the months of July to September, 2018. The facility offers varied services, including antenatal care, and has admission capacity of about 12–18 patients daily. It is located along Musita-Lumino Busia highway Mayuge district, Mayuge Town council, Busoga sub-region in East-central Uganda. It supports the neighboring districts of Bugiri, Iganga and Jinja.

The study population comprised consented pregnant women aged 18–49 years, who did not know their HIV and syphilis sero-status. The study excluded pregnant women who reported with a known positive HIV or syphilis test and obstetric emergency. Participants who were HIV and syphilis positive sero-positive were channelled directly to care. Sample size was determined using Kish Leslie formula [20], given as \( n = \frac{Z^2pq}{d^2} \). Using 50% estimated proportion of HIV/Syphilis co-infection and an allowable error of 5%; a sample size of 382 was considered.

The study used an interviewer administered questionnaire and laboratory analysis of blood samples to obtain data. The questionnaire captured socio-demographic and exposure history of the study participants. In addition, three laboratory personnel involved in the sample analyses were given feasibility questionnaires to assess the usability of the SD Bioline HIV/Syphilis Duo Kit compared to the routine single HIV and syphilis test methods. This focused on the ease of the test method, mean time to results, sample volumes used in each assay, and ease of result interpretation. The laboratory assays were done by two laboratory technicians attached to the Mayuge Health centre III. For the purpose of this research, these technicians were trained on the use of SD Bioline HIV/Syphilis Duo assay prior to initiation of the study. On a single day, one technician performed all the SD Bioline assays, while the other performed the Determine/Statpak/Unigold for HIV, and TPHA for syphilis. These were rotated daily, and a third technician (Principal Investigator) oversaw the entire process. The two laboratory technicians were blinded to each other’s results, and a third reader (Principal Investigator) was considered for discrepant results of the two test assays, and also to resolve such results that were not obvious to conclude.

About 2 mL of blood samples were collected using Ethylene di-amino tetra acetic acid (EDTA) vacutainer. The laboratory technician attached to the antenatal care clinic laboratory used about 20 µL of the venous blood to perform the SD Bioline assay. The remaining blood samples were transported in a cool box maintained at 2–8 °C using frozen icepacks to the HIV clinic where they were separated by centrifugation (Thermo SCIENTIFIC, CL10 Centrifuge) at 3000 revolutions per minute for 10 min, and plasma was transferred into 2 mL pre-labelled SARSTEDT cryotubes (Aktiengesellschaft & Co, D-51588 Numbrecht, Germany). A portion of this plasma was used to perform the single HIV and syphilis testing, as defined in the national algorithm. If testing was not done on the same day of specimen collection, plasma were kept at 2–8 °C for not more than 24 h before analysis. Test were carried out according to the manufacturer’s kit instructions that were embodied into respective standard operating procedures (SOPs). The presence of one band (C) indicated a negative result, while the (C) and HIV bands indicated a positive HIV result, the C and syphilis bands were indicative of positive syphilis test, and the C, HIV and syphilis bands indicated syphilis and HIV dual infection. Syphilis was confirmed using Treponema pallidum Hemagglutination assay (BIOTEC Lab21 Healthcare Ltd, Dorset, UK), while HIV was confirmed using the established algorithm in which samples were tested serially with; (a) Determine HIV-1/2 (Abbott Laboratories, Abbott Park, Ireland), (b) HIV 1/2 Stat-Pak™ (Chembio Diagnostic Systems, Medford, New York 11763, USA) and (c) Uni-Gold recombinant HIV-1/2 (Trinity Biotech, Bray, Ireland) assays. Using this approach, a negative first assay was considered negative, while a positive first assay was followed by testing using Statpak and confirmed with Uni-Gold Recombinant HIV1/2 assay (Trinity Biotech, Bray, Ireland). The test bands were interpreted appropriately by two independent laboratory technicians, were a discordancy was observed, a third read was considered. The flow of laboratory testing is summarized in Fig. 1.

Data were analyzed using frequency tables. The operational performance was determined based on measurement of Sensitivity, specificity, positive predictive value and negative predictive value of the Duo Kit were calculated. Sensitivity = \( \frac{TP}{TP + FN} \); Specificity = \( \frac{TN}{FP + TN} \). Agreement between the test methods was assessed using the Cohen’s kappa coefficient (κ value). The feasibility of
the SD Bioline HIV/Syphilis Duo assay was determined by ease of the test method, turnaround time and ease of result interpretation.

Ethical approval was obtained from the research and ethics committee of Clarke International University. Permission to carry on research was obtained from the District Health Officer, and Mayuge Health Centre III in-charge. This study was voluntary, and written informed consent was sought from each study participant.

Results

The study enrolled 382 consented healthy pregnant women. Their mean age was 25.8 years (SD = 5.977) IQR = 9.57. Majority (32.7%; N = 125) of the participants were aged 20–24 years, 52.1% (N = 199) had completed primary level, and 65.7% (N = 251) were in a monogamous relationship. Their socio-demographic characteristics are given in Table 1.

Seven of the participants tested positive for HIV, giving a prevalence of 1.8% (95% confidence interval 1.23–2.41). Eight participants tested positive for syphilis, giving a prevalence of 2.1% (95% confidence interval 1.61–2.54). The prevalence of HIV and syphilis dual infection was 2 out of 382 (0.52%; 95% CI 0.37–0.92). Summary of the diagnostic performance is given in Table 2. Results of the Cohen's Kappa are given in Additional file 1: Table S1.

Discussion

There are numerous efforts to routinely screen for HIV and syphilis infections among pregnant women. This requires the use of highly sensitive, low cost and rapid point-of-care tests to aptly diagnose and initiate care. One such invention is the SD Bioline HIV–Syphilis Duo assay that comes with the desired attributes. From this study, the HIV prevalence of 1.8%, is less than the overall country prevalence of 6.2%, and also that among the Ugandan women of child bearing age that was reported at 7.5% [21]. The sizably lower prevalence of HIV than the national estimates is attributed in part to increased sexual health education initiatives [22]. The prevalence of syphilis was 2.1%, a value close to the nationally documented prevalence of 2.2% among adult Ugandan [21]. In spite of the seemingly lower prevalence values of HIV and syphilis infections from this study, the rates remains unacceptably high, and may portend the global efforts
towards the elimination of the dual infection. To this, there is need to upsurge detection of the dual infection and the associated sequelae [22–25].

The diagnostic performance of the SD Bioline HIV–Syphilis Duo Kit as measured by sensitivity and specificity was 100.0%. This is in agreement with previous studies that reported higher sensitivities for syphilis (100.0, and 99.7%, respectively) and comparable sensitivities for HIV (99.1, and 100%, respectively) [14, 26–30]. The observed high syphilis sensitivity of the SD Bioline Duo Kit is explained by the variance in the infection stage, as earlier studies suggested [31–33]. This study contributes to the growing evidence in support of high diagnostic performance of the assay in a resource-limited setting. This brings with sufficient evidence to implement the dual assay in abide to achieve the double elimination. The SD Bioline assay showed great attributes of use, including a shortened turnaround time (20 min), being user friendly, use of micro volumes that may warrant its performance using capillary blood sample. The assays still befits the economic pressure of limited resource setting as it costs about 2 United States Dollar versus 2 United States Dollar for TPHA and 3–10 United States Dollar for the standard HIV algorithm [14]. In addition, the assay could bridge the high workload of testing HIV and syphilis separately as seen in most health facilities, and this has proven ideal for our setting as personnel capacities remains below the required. Although the results of this study are reassuring of excellent operational performance of the assay, we did not evaluate its performance with capillary blood, in particular figure prick samples. Also, there were few number of positives for HIV and syphilis infections; this in a way makes the results of sensitivity and specificity to be biased. In addition, the study did not use the rapid plasma regain (RPR) to screen for active infections, and also gold standard polymerase chain reaction assays.

**Conclusion**

This study reports an optimal operational performance of SD Bioline HIV/Syphilis Duo Kit, which reaffirms the already established scientific finding. This makes it suitable for the integration in the testing and treatment programs to ultimately eliminate the dual infection. With its price point and ease of use, it is irrefutable that this assay suites the operation in a limited resource setting to control and manage sexually transmitted infections. This RDT kit offers an opportunity for simultaneous screening of both HIV and syphilis in pregnant women across our antenatal care and prevention of mother to child transmission (PMTCT) programs. However, for country wide rollout, a performance evaluation of the national HIV test algorithm with a consideration of the SD Bioline HIV/Syphilis Duo RDT as a first test is recommended.

**Table 1 Showing the socio-demographic factors of study participants (n = 382)**

| Variable                  | Frequency | Percentage |
|---------------------------|-----------|------------|
| **Age category (years)**  |           |            |
| ≤ 19                      | 57        | 14.9       |
| 20–24                     | 125       | 32.7       |
| 25–29                     | 96        | 25.1       |
| ≥ 30                      | 104       | 27.2       |
| **Religion**              |           |            |
| Catholic                  | 113       | 29.6       |
| Protestant                | 107       | 28.0       |
| Muslim                    | 23        | 6.0        |
| Pentecostal               | 123       | 32.2       |
| Others                    | 16        | 4.2        |
| **Education level**       |           |            |
| None                      | 61        | 16.0       |
| Primary                   | 199       | 52.1       |
| Secondary                 | 88        | 23.0       |
| Tertiary                  | 16        | 4.2        |
| University                | 18        | 4.7        |
| Self employed             | 241       | 63.1       |
| **Occupation**            |           |            |
| Employed                  | 49        | 12.8       |
| Unemployed                | 92        | 24.1       |
| Marital status            |           |            |
| Married                   | 279       | 73.0       |
| Divorced                  | 26        | 6.8        |
| Widowed                   | 06        | 1.6        |
| Others                    | 71        | 18.6       |
| **Type of marriage**      |           |            |
| Monogamous                | 251       | 65.7       |
| Polygamous                | 69        | 18.1       |
| Others                    | 62        | 16.2       |
| **Exposure risk to HIV**  |           |            |
| Yes                       | 79        | 20.7       |
| No                        | 303       | 79.3       |
| **Exposure risk to syphilis** |     |            |
| Yes                       | 143       | 37.4       |
| No                        | 239       | 62.6       |
Limitation of the study
There are shortfalls of this study, the use of venous blood which was centrifuged and tested in a laboratory as opposed to point-of care whole blood specimens obtained from a figure prick. Also, the study did not elucidate the PCR confirmation of the duo-infection as the gold standard diagnosis.

Additional file

Additional file 1: Table S1. Results of the Cohen's Kappa.

Abbreviations
HIV: human immune deficiency virus; RDTs: rapid diagnostic tests; STIs: sexually transmitted infections; TPHA: Treponema Pallidum Hemagglutination Assay; WHO: World Health Organization.

Authors’ contributions
IMT, TA, BM and CA conceived the study idea, participated in study design; data acquisition, analysis, and interpretation; and manuscript drafting and revision. CA and IMT participated in drafting data collection tools and scheduling for internal responsibilities. BM and TA drafted and revised the manuscript. IMT and CA critically reviewed the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Medical Laboratory Sciences, Clarke International University, PO Box 7782, Kampala, Uganda. 2 Institute of Public Health and Management, Clarke International University, PO Box 7782, Kampala, Uganda.

Acknowledgements
The authors are grateful to the study participants, and all staffs of antenatal clinic unit, Mayuge Health Centre III. We wish to express our deepest gratitude to the District Health Officer for the support accorded. We acknowledge the logistic support of the HIV–Syphilis SD Bioline test kits that were donated by MEDLINK LAB & SURGICALS LTD.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
We did not obtain consent to share data obtained from the questionnaire, however the datasets used and/or analyzed during the current study available from the corresponding author on request.

Consent to publish
Not applicable.

Ethics approval and consent to participate
We received ethical approval from Clarke International University (Formerly, International Health Sciences University Research Ethics Committee (REC). All respondents provided written informed consent after receiving detailed description of the study. Eligible participants were consented in privacy and no incentives were given. Anonymity of the respondents was ensured at all stages of data analysis.

Funding
We did not receive any funding for this study, however, the principal investigator (IMT) received a donation of HIV–Syphilis SD Bioline test kits from MEDLINK LAB & SURGICALS LTD. This did not in any way interfere with the design of the study, result analysis and the decision to publish.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 22 March 2019 Accepted: 15 April 2019 Published online: 25 April 2019

References
1. Eticha Schmid G, Rowley J, Samuelson J, et al. Global incidence and prevalence of four curable sexually transmitted infections (STIs): new estimates from WHO. 2013.
2. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. Geneva: World Health Organization; 2014.
3. World Health Organization. Global Guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and Syphilis. Geneva: World Health Organization; 2015.
4. Newman L, Kamb M, Hawkes S, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med. 2015;10(2):e1001396.
5. Centre for Disease Control and Prevention. The World Bank. Sexually transmitted infections in developing countries: current concepts and strategies on improving STI prevention, treatment, and control. Washington, DC; The World Bank, 2015.

6. Uganda-prevalence of syphilis (% of women attending antenatal care). https://tradingeconomics.com/uganda/prevalence-of-syphilis-percentage-of-women-attending-antenatal-care-wb-data.html. Accessed 23 Nov 2018.

7. Government of Uganda; UNGASS Country Progress Report January 2008–December 2009. 2010. http://data.unaids.org/pub/Report/2010/uganda_2010_country_progress_report_en.pdf. Accessed 23 Nov 2018.

8. Ishikawa N, Newman L, Taylor MM, Essaje S, Ghidinelli M, Pendse R. Elimination of mother-to-child transmission of HIV and syphilis—an achievement of universal health coverage? Bull World Health Organ. 2016;14:e1003196.

9. Newman L, Kamb M, Hawkes S, Gomez G, Say L, Seuc A, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med. 2013;10(2):e1001396.

10. World Health Organization. Investment case for eliminating mother-to-child transmission of syphilis. 2012.

11. World Health Organization. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis. Geneva: WHO; 2014.

12. WHO. Information note on the use of dual HIV/syphilis rapid diagnostic tests (RDT). 2017. http://apps.who.int/iris/bitstream/handle/10665/252849/WHO-RHR-17.01-eng.pdf?sequence=1.

13. SD Bioline HIV/Syphilis DUO. https://www.alere.com/en/home/products-detail-sd-bioline-hv-syphilis-duo.html. Accessible 6 June 2018.

14. Omoding D, Katavera V, Siedner M, Boum Y. Evaluation of SD Bioline HIV/syphilis Duo assay at a rural health center in Southwestern Uganda. BMC Res Notes. 2014;7:476.

15. Shimelis T, Tadesse E. The diagnostic performance evaluation of the SD Bioline HIV/Syphilis Duo rapid test in southern Ethiopia: a cross-sectional study. BMJ Open. 2015;5(4):e007371. https://doi.org/10.1136/bmjopen-2014-007371.

16. Black V, Williams BG, Maseko V, Radebe F, Rees H, Lewis DA. Field evaluation of standard diagnostics’ Bioline HIV/syphilis duo test among female sex workers in Johannesburg, South Africa. Sexually Transm Infect. 2016. https://doi.org/10.1136/sextrans-2015-052474.

17. Shyka G, Singh DP, Ojha HC, Ojha CR, Mishra SK, et al. Evaluation of SD Bioline HIV/syphilis Duo Rapid test kits in Nepal. BMC Infect Dis. 2016;16:450. https://doi.org/10.1186/s12879-016-2649-4.

18. Bristow C, Leon SR, Huang E, Brown B, Ramos LB, Vargas SK, et al. Field evaluation of a dual rapid diagnostic test for HIV infection and syphilis in Lima, Peru. Sex Transm Infect. 2016;92:182–5. https://doi.org/10.1136/sextrans-2015-052526.

19. World Health Organization. WHO prequalification of in vitro diagnostics programmes public report. Product: SD Bioline HIV/syphilis Duo. Number PQx 0179-012-00. 2015.